#MGI Tech #South Africa #Cape Town #SAMRC #DSTI

MGI Tech Partners with SAMRC and DSTI to Launch Groundbreaking Genomic Initiative in South Africa

In a significant advancement for African genomics, MGI Tech Co., Ltd. has joined forces with the South African Medical Research Council (SAMRC) and the Department of Science, Technology and Innovation (DSTI) to unveil a major genomic initiative. This collaboration was officially announced on November 11, 2025, during an event in Cape Town, where two remarkable developments were introduced: the launch of Africa's first DNBSEQ-T7 sequencing platform and the initiation of the 110K Human Genome Program in South Africa.

Transforming Genomic Research in South Africa

The unveiling of the DNBSEQ-T7 at SAMRC represents a groundbreaking leap in the capabilities of genomic research within Africa. This ultra-high-throughput sequencing platform is designed to facilitate large-scale genomic studies, allowing for rapid data generation with unparalleled accuracy. Its introduction is anticipated to significantly decrease the costs and enhance accessibility for genomic research across the continent, making high-throughput sequencing available to a wider range of researchers and clinicians.

Professor Ntobeko Ntusi, CEO and President of the SAMRC, highlighted the importance of this partnership by stating that it symbolizes a strategic investment in developing local capacity and affordable genomic sequencing infrastructure. He emphasized how this collaboration with MGI would enhance national sustainability and scalability, enabling South Africa to provide population-scale genomics at feasible costs.

The DNBSEQ-T7: A Game Changer

As the flagship technology of this initiative, the DNBSEQ-T7 stands out for its ability to generate vast amounts of genomic data quickly. This advancement opens new opportunities for multi-omics studies, which have the potential to revolutionize the field of genomics by integrating data from various biological layers. The SAMRC Genomics Platform, which has been pivotal in advancing precision medicine in South Africa, will now be empowered to support innovative research initiatives with this state-of-the-art facility.

Beyond its sequencing capabilities, the SAMRC Genomics Center plays a critical role in promoting local research talent. The center is dedicated to training and mentoring emerging researchers and developing bioinformatics pipelines tailored to the unique genetic diversity found in African populations. This commitment to building local expertise aims to enhance South Africa's ability to not only participate in but also lead in the rapidly evolving field of genomics.

The 110K Human Genome Program

The introduction of the 110K Human Genome Program marks another landmark moment for South African genomics. This ambitious initiative aims to sequence 110,000 South African genomes, filling a significant gap in the global representation of African genomic data. Glaudina Loots, the Director for Health Innovation at DSTI, described this partnership as a critical step towards realizing the country’s vision for precision medicine.

During its pilot phase, the program will focus on sequencing up to 10,000 genomes, establishing a comprehensive national genomic reference database. This resource is expected to be invaluable for understanding population-specific genetic diversity and furthering the diagnosis, prevention, and treatment of diseases that are prevalent in Africa.

The initiative goes beyond mere data collection; it aims to enhance the health innovation landscape in South Africa by integrating infrastructure development, standardized pricing, and capacity building efforts. The collaboration also presents opportunities for joint funding through various international science collaboration platforms, reinforcing a commitment to South-South cooperation.

Looking Ahead

MGI Tech’s President, Duncan Yu, underscored that the journey towards genomic advancement is fueled by partnerships. He expressed pride in collaborating with SAMRC and DSTI to facilitate the establishment of South Africa as a central hub for high-quality genomic research. This partnership not only aims to address the historical underrepresentation of African genetic data but also aspires to support broader goals of scientific independence and health equity.

As the 110K Human Genome Program progresses, MGI's involvement signifies a promise to empower African scientists and contribute to tackling the health challenges unique to the continent. By cultivating local capabilities in genomic research, South Africa is poised to emerge as a leader in the era of precision medicine, with the DNBSEQ-T7 playing a pivotal role in driving innovation forward.

This collaboration heralds a new chapter in African genomics, allowing the rich genetic tapestry of the continent to be represented in the global scientific community. The outcomes of this initiative are anticipated to not only improve health outcomes in South Africa but also significantly enhance the capacity for genomic research across the African continent.